Trial Profile
Multicenter, Placebo-controlled, Long-term Study of Depigoid Birch 5000 in Adults and Adolescents With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Acronyms Depigoid Birch
- Sponsors LETI Pharma GmbH
- 01 Nov 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 This trial has been completed in Germany.
- 15 Sep 2018 This trial has been completed in Finland, Lithuania and Latvia (end date: 2018-07-30)